Codexis, Inc.
Every calculator, already run for CDXS
Open the full toolkit →You have the numbers on CDXS. Get the argument.
A written report on which of these readings actually decide the outcome for Codexis, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering CDXSAnalyst Price Target Disagreement for Codexis, Inc.
Wall Street's bull case implies +700% from the current price; the bear case implies +45%. A 655% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CDXS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Codexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS — frequently asked
Is CDXS a buy right now?
Wall Street's consensus rating on Codexis, Inc. is Buy across 8 analysts, with a mean price target of $6.14 (+347% vs. the current $1.38). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CDXS overvalued?
CDXS trades at — trailing earnings, against a DCF fair value of $0 per share. The current price implies 31% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is CDXS's next earnings date?
Codexis, Inc. is next scheduled to report earnings around Nov 5, 2026. A full CDXS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Codexis, Inc.?
Analysts covering Codexis, Inc. (CDXS) range from a bear-case target of $2.00 to a bull-case high of $11.00, with a mean consensus target of $6.14 across 7 analysts. The spread of $9.00 (655% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Codexis, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Codexis, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CDXS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Codexis, Inc., in minutes. 3 free reports included with every account — no credit card required.